top of page


Principal investigator: 

  • MUSE Phase 2+3

  • Intracavernöse Applikation von Prostaglandin bei Querschnittsgelähmten

  • AUO AP17/95 intermittierende versus kontinuierliche Suppression von Androgen bei Patienten mit Prostatakarzinom

  • AUO AP33/02 Phase II study: Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition

  • AUO AP36/03 Bicaltamide +/- Radiotherapie bei Patienten mit PSA Anstieg nach radikaler Prostatektomie

  • AUO AP38/03 ZEUS Open randomized multicenter study investigating the efficacy and tolerance of Zometa (zoledronic acid) in patients with high-risk prostate cancer

  • GOLIATH A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate with the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia” Protocol PE1006

bottom of page